Trial document

drksid header


Trial Description

start of 1:1-Block title


Quality of life in patients with localised prostate cancer after either computerassisted surgery or radiotherapy with protons and photons.

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

We want to compare quality of life in prostate cancer patients undergoing two different therapies. One therapy is a computerassisted surgery, the other is radiotherapy with protons and photons.
We want to find out if patients differ in their quality of life parameters within one year after therapy.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Besides other options patients with localised prostate cancer can choose between radical prostatectomy and external beam radiation therapy. Both therapies have similar success rates.
In Heidelberg two up-to-date methods: computerassisted surgery and radiotherapy with protons and photons are implemented.
Aim of this study is to randomise patients to one of these methods and to evaluate possible differences in quality of life within one year after treatment. Secondary objectives are medical outcome, other aspects of quality of life and well-beeing of spouses. We also want to find out why patients participate in randomised studies.
The interdisciplinary project includes physicians, psychooncologists and statisticians of different departements of the University Clinic Heidelberg.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003569
  •   2012/03/06
  •   [---]*
  •   yes
  •   Approved
  •   S-008/2012, Ethik-Kommission I der Medizinischen Fakultät Heidelberg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C61 -  Malignant neoplasm of prostate
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   computerassisted surgery
  •   radiotherapy with protons and photons
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Quality of life after treatment and after 2 weks, 3, 6, 9 and 12 month. Questionnaires: EORTC-C30, EORTC-PR25, ICS, IIEF5, PHQ, CCAT-P.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Before, directly after and 2 weeks, 3 month, 6 month ans 1 year after treatment:
Biochemical relapse-free prostate-specific survival
Side effects (ICS, IIEF5)
Depression (PHQ)
Anxiety (PHQ)
Contentment (Distress-scale, CCAT-P, interview)
fear of progression (PA-F-KF)
Contentment of spouse (Distress-scale, EPIC, PHQ, interview)

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Planned
  •   2012/04/12
  •   120
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Male
  •   40   Years
  •   75   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. ECOG Performance Status 0 or 1
2. informed concent
3. prostate cancer (<cT3, PSA<20 ng/ml, Gleason-Score<8)
4. ability to read and answer German questionnaires

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1. Medical reasons against one of the therapies
2. Other treatments of prostate cancer
3. Metastases
4. Life expectancy < 5 years
5. Patients with legal guardian
6. Participation in other studies that could influence the results
7. Cardiac pacemaker

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Europäische Stiftung für Urologie Heidelberg (EFU)
    • INF 110
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
  • start of 1:1-Block address otherSupport
    • Universitätsklinikum Heidelberg
    • Im Neuenheimer Feld 672
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    end of 1:1-Block address contact otherSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting withdrawn before recruiting started
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.